We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Last Friday, Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined significantly when compared to the previous year. Adjusted loss was ...